ClinicalTrials.gg
CompletedNCT04299048Updated Dec 14, 2023Results posted

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

A Phase 1 interventional study of PF-06946860 in Cachexia, Non-Small-Cell Lung Cancer and Pancreatic Cancer, sponsored by Pfizer. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.

Enrollment
60th of 72
11 · median 51
Started
2020
with 1 other
Phase 1
21 of 95
2 open now
Registered
75th of 95
by date
Lead sponsor
6 of 95
Pfizer

Among the 95 studies in Cachexia with a site in United States, this one is the 60th largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2020, is one of 21 in phase 1, and was the 75th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Cachexia with a site in United States, or all of them as a file.
02

Study summary

Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.

Read the detailed description

This 12-week open-label study will explore how PF-06946860 is tolerated, the effects of the study drug, the best dose for treatment and how participants with non-small cell lung, pancreatic or colorectal cancer and cachexia feel after receiving repeated subcutaneous dosing. During the 12-week treatment period, study drug will be administered subcutaneously every 3 weeks for a total of 5 doses. There is a 12-week follow-up period following the last dose of study drug. Additional assessments include:

  • body weight measurements
  • blood pressure and heart rate measurements
  • Lumbar Skeletal Muscle Index (LSMI) by CT scan
  • Blood samples:

    • to evaluate safety,
    • to measure the amount of the study drug in the blood,
    • to evaluate if the study drug causes an immune response,
    • to examine the effects of the study drug on levels of a specific cytokine,
    • and for exploratory samples for bio banking.
  • Measure the impact of the study drug on appetite, nausea, vomiting, fatigue, physical function, and health-related quality of life with questionnaires.
  • Measure the impact of study drug on physical activity using wearable digital sensors.
  • To evaluate the effect of study drug on ability to complete anti-tumor treatment and survival in participants with cancer and cachexia.
  • To evaluate tumor size.
03

Conditions studied

  • Cachexia
  • Non-Small-Cell Lung Cancer
  • Pancreatic Cancer
  • Colorectal Cancer

Keywords

  • cachexia, non-small cell lung cancer, pancreatic cancer
  • colorectal cancer, weight loss, anorexia, muscle loss, fatigue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented histologic or cytologic diagnosis of advanced NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer.
  • Cachexia, defined by \<20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening or Involuntary weight loss of >5% within 6 months prior to screening irrespective of BMI or If medical record documentation is unavailable, patient's report will suffice to estimate involuntary body weight loss.;
  • Will receive the following for non-small cell lung cancer:

    • a platinum + pemetrexed ± pembrolizumab or
    • a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or
    • pembrolizumab alone
  • Will receive the following for pancreatic cancer:

    • FOLFIRINOX or
    • Nab-Paclitaxel + Gemcitabine
    • Gemcitabine
  • Will receive the following for colorectal cancer:

    • FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
    • FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
    • FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or
    • Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti-cancer treatment/ therapy.
  • Adequate renal and liver function.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • All other forms of cancers not specified above unless currently considered cured (>5 years without evidence of recurrence).
  • Planned radiation therapy as part of the primary anti-tumor therapy regimen. However, localized radiation therapy for symptomatic relief is permitted
  • Cachexia caused by other reasons: Severe requiring use of home O2, heart failure or AIDS.
  • known symptomatic requiring .
  • Active or C virus.
  • Confirmed positive test.
  • Current active reversible causes of decreased food intake.
  • Receiving tube feedings or parenteral nutrition at Screening.
  • Elevated blood pressure that cannot be controlled by medications.
  • Women who are pregnant or breast-feeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    PF-06946860

    subcutaneous injection

    Drug: PF-06946860

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

    Time frame: From Day 1 up to Week 24

  2. Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

    Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin\< 0.8x lower limit of normal (LLN); Hematocrit\< 0.8x LLN; Erythrocytes (Ery.)\< 0.8x LLN; Ery. Mean Corpuscular Volume\< 0.9x LLN; Leukocytes\< 0.6x LLN; Lymphocytes\< 0.8x LLN; Bilirubin\> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase\> 3.0x ULN; Alkaline Phosphatase\> 3.0x ULN; Protein\< 0.8x LLN; Sodium\< 0.95x LLN; Chloride\< 0.9x LLN; Calcium\< 0.9x LLN; Bicarbonate\< 0.9x LLN; Glucose\> 1.5x ULN; C Reactive Protein\> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts \>1/LPF.

    Time frame: From Day 1 up to Week 24

  3. Number of Participants With Post-Baseline Vital Signs Abnormalities

    Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \<40 beats per minute (bpm) or \>120 bpm.

    Time frame: From Day 1 up to Week 24

  4. Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

    ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\< value ≤480 msec, 480\< value ≤500 msec, value \>500 msec, and 30\< change ≤60 msec, change \>60 msec.

    Time frame: From Day 1 up to Week 24

Secondary outcomes

  1. Serum Unbound Trough Concentrations (Ctrough) of PF-06946860

    Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum unbound Ctrough was summarized by time and treatment group.

    Time frame: Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15

  2. Serum Total Ctrough of PF-06946860

    Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum total Ctrough was summarized by time and treatment group.

    Time frame: Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15

07

Results

Posted Dec 14, 2023

Participant flow

Participant flow — Overall Study
MilestonePF-06946860 Q3W
Started11
Treated10
Completed7
Not completed4
Withdrew: Death1
Withdrew: Global deterioration of health status2
Withdrew: Enrolled and not treated1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs.

Time frame:
From Day 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsPF-06946860 Q3W
AEs10
SAEs4
PrimaryNumber of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)

Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin\< 0.8x lower limit of normal (LLN); Hematocrit\< 0.8x LLN; Erythrocytes (Ery.)\< 0.8x LLN; Ery. Mean Corpuscular Volume\< 0.9x LLN; Leukocytes\< 0.6x LLN; Lymphocytes\< 0.8x LLN; Bilirubin\> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase\> 3.0x ULN; Alkaline Phosphatase\> 3.0x ULN; Protein\< 0.8x LLN; Sodium\< 0.95x LLN; Chloride\< 0.9x LLN; Calcium\< 0.9x LLN; Bicarbonate\< 0.9x LLN; Glucose\> 1.5x ULN; C Reactive Protein\> 1.1x ULN; for urinalysis, Urine Glucose ≥1, Ketones ≥1, Urine Protein ≥1, Urine Hemoglobin ≥1, Urobilinogen ≥1, Nitrite ≥1, and Leukocyte ≥1 Esterase ≥1; Hyaline Casts \>1/LPF.

Time frame:
From Day 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
ParticipantsPF-06946860 Q3W
Hemoglobin (g/dL)< 0.8x LLN2
Hematocrit (%)< 0.8x LLN2
Erythrocytes (10^6/mm^3)< 0.8x LLN2
Ery. Mean Corpuscular Volume (um^3)< 0.9x LLN1
Leukocytes (10^3/mm^3)< 0.6x LLN2
Lymphocytes (10^3/mm^3)< 0.8x LLN3
Bilirubin (mg/dL)> 1.5x ULN1
Aspartate Aminotransferase (U/L)> 3.0x ULN1
Alkaline Phosphatase (U/L)> 3.0x ULN2
Protein (g/dL)< 0.8x LLN1
Sodium (mEq/L)< 0.95x LLN1
Chloride (mEq/L)< 0.9x LLN1
Calcium (mg/dL)< 0.9x LLN1
Bicarbonate (mEq/L)< 0.9x LLN2
Glucose (mg/dL)> 1.5x ULN4
C Reactive Protein (mg/dL)> 1.1x ULN5
URINE Glucose ≥13
Ketones ≥11
URINE Protein ≥11
URINE Hemoglobin ≥12
Urobilinogen ≥11
Nitrite ≥11
Leukocyte Esterase ≥12
Hyaline Casts >1/LPF2
PrimaryNumber of Participants With Post-Baseline Vital Signs Abnormalities

Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline ≥30 mmHg; supine diastolic blood pressure (DBP) \<50 mmHg, supine DBP increase/decrease from baseline ≥20 mmHg; supine pulse rate \<40 beats per minute (bpm) or \>120 bpm.

Time frame:
From Day 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Vital Signs Abnormalities
ParticipantsPF-06946860 Q3W
Supine SBP - Value <90 mmHg0
Supine SBP - Change ≥ 30 mmHg Increase2
Supine SBP - Change ≥ 30 mmHg Decrease0
Supine DBP - Value <50 mmHg0
Supine DBP - Change ≥ 20 mmHg Increase1
Supine DBP - Change ≥ 20 mmHg Decrease0
Supine Pulse Rate - Value <40 bpm0
Supine Pulse Rate - Value >120 bpm0
PrimaryNumber of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities

ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value ≥300 milliseconds (msec), percentage change ≥25/50%; QRS interval: value ≥140 msec, percentage change ≥50%; QT interval: value ≥500 msec; QTcF interval: 470\< value ≤480 msec, 480\< value ≤500 msec, value \>500 msec, and 30\< change ≤60 msec, change \>60 msec.

Time frame:
From Day 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities
ParticipantsPF-06946860 Q3W
Supine PR Interval - Value ≥300 msec0
Supine PR Interval - %Chg ≥25/50%0
Supine QRS Interval - Value ≥140 msec0
Supine QRS Interval - %Chg ≥50%0
Supine QT Interval - Value ≥500 msec0
Supine QTcF - 470<Value≤480 msec0
Supine QTcF - 480<Value≤500 msec0
Supine QTcF - Value>500 msec0
Supine QTcF - 30<Chg≤60 msec2
Supine QTcF - Chg>60 msec0
SecondarySerum Unbound Trough Concentrations (Ctrough) of PF-06946860

Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum unbound Ctrough was summarized by time and treatment group.

Time frame:
Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
Reported as:
Geometric mean · ng/mL
Serum Unbound Trough Concentrations (Ctrough) of PF-06946860
ng/mLPF-06946860 Q3W
Week 34.041 ± 1.28*10^19
Week 61690 ± 593
Week 9610.9 ± 7.79*10^10
Week 124383 ± 142
Week 15560.5 ± 2.15*10^12
SecondarySerum Total Ctrough of PF-06946860

Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum total Ctrough was summarized by time and treatment group.

Time frame:
Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
Reported as:
Geometric mean · ng/mL
Serum Total Ctrough of PF-06946860
ng/mLPF-06946860 Q3W
Week 310050 ± 19
Week 617010 ± 16
Week 920740 ± 24
Week 1221310 ± 32
Week 1525450 ± 31

Adverse events

Collected over From Day 1 up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-06946860 Q3W1/10 (10%)4/10 (40%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventPF-06946860 Q3W
AnaemiaBlood and lymphatic system disorders1/10
Cholecystitis acuteHepatobiliary disorders1/10
SepsisInfections and infestations1/10
Transaminases increasedInvestigations1/10
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/10
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPF-06946860 Q3W
AnaemiaBlood and lymphatic system disorders5/10
DiarrhoeaGastrointestinal disorders5/10
NauseaGastrointestinal disorders4/10
FatigueGeneral disorders4/10
Lacrimation increasedEye disorders2/10
Abdominal pain upperGastrointestinal disorders2/10
VomitingGastrointestinal disorders2/10
FallInjury, poisoning and procedural complications2/10
Neutrophil count decreasedInvestigations2/10
Platelet count decreasedInvestigations2/10

Baseline characteristics

The baseline analysis was performed on treated participants.

Age, Categorical
Age, Categorical(Participants)PF-06946860 Q3W
<=18 years0
Between 18 and 65 years4
>=65 years6
Sex: Female, Male
Sex: Female, Male(Participants)PF-06946860 Q3W
Female3
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PF-06946860 Q3W
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PF-06946860 Q3W
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White7
More than one race0
Unknown or Not Reported1
Body Mass Index
Body Mass Index(kg/m^2)PF-06946860 Q3W
Median22.88 (17.31 to 30.87)
08

Study locations

10 sites
  • Beverly Hills Cancer Center
    Beverly Hills, California 90211, United States
  • SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center
    Grand Junction, Colorado 81501, United States
  • Lutheran Medical Center
    Wheat Ridge, Colorado 80033, United States
  • Tallahassee Memorial Healthcare Cancer Center
    Tallahassee, Florida 32308, United States
  • Fort Wayne Medical Oncology and Hematology, Inc.
    Fort Wayne, Indiana 46804, United States
  • New England Cancer Specialists
    Scarborough, Maine 04074, United States
  • American Oncology Partners of Maryland, PA
    Bethesda, Maryland 20817, United States
  • American Oncology Partners of Maryland, PA
    Germantown, Maryland 20874, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • VA Puget Sound Health Care System
    Seattle, Washington 98108, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2022, 16 months.

Results were first posted in Dec 2023, 1 year 8 months after primary completion.

Of 21 phase 1 interventional studies under Cachexia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2020
First posted
Mar 6, 2020
StartActual
Nov 17, 2020
Primary completionActual
Mar 30, 2022
CompletionActual
Mar 30, 2022
Results first posted
Dec 14, 2023
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04299048
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 6, 2020
Start date
Nov 17, 2020
Primary completion
Mar 30, 2022
Completion
Mar 30, 2022
Results posted
Dec 14, 2023
Last update
Dec 14, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponsegromab

Start the discussion